Business Wire

ADDMEDICA Receives FDA-Approval for Orphan Drug Siklos®, First and Sole Hydroxyurea-Based Treatment* for Paediatric Patients with Sickle Cell Anaemia.

Jaa

ADDMEDICA has announced that the US Food and Drug Administration (FDA) has approved Siklos® (hydroxyurea tablets) in paediatric patients, two years of age and older, suffering from sickle cell anaemia.

Approval was obtained under a priority review and orphan drug designation.

Particularly suitable for paediatric populations, Siklos® offers dosing options to facilitate adjustment based on the patient’s weight to obtain the best efficacy/tolerance ratio for each child throughout the growth years.

FDA-approval of Siklos® was granted based on efficacy and safety data collected in a cohort study, Escort-HU, which included several hundred child and adult patients treated with Siklos® in Europe.

According to François Anger, President of ADDMEDICA:

“FDA-approval of Siklos® is a major breakthrough in the treatment of American children with sickle cell anaemia. European patients have been benefitting from Siklos®, the only form of hydroxyurea indicated in paediatric care in the world, since 2007. This successful outcome can also be attributed to the patients who agreed to participate in the Escort-HU study and the physicians who allowed it to happen. With the new FDA-approval, ADDMEDICA consolidates its leadership in the treatment of sickle cell anaemia by continuing to invest in the development and availability of this essential therapeutic product in new countries.”

Siklos® will be marketed in the United States by Medunik USA Inc.

“We’re pleased to partner with ADDMEDICA to distribute this orphan drug which is recognised as the reference drug treatment in sickle cell anaemia. It will improve the health and quality of life of hundreds of children with the disease in the United States,” said Éric Gervais, Executive Vice-President of Medunik. “The launch of Siklos® in the next few months establishes our footprint in the United States in orphan drug therapies and is the latest in a series of significant milestones for the company.”

About sickle cell anaemia

Sickle cell anaemia is a particularly disabling disease, whose most common acute manifestations are painful vaso-occlusive crises in the bones, lungs (acute chest syndrome) and most vascularised organs, and strokes. It may be life-threatening, especially in the case of acute chest syndrome.

The disease is caused by abnormal haemoglobin molecules causing red blood cells to become stiff and sickle-shaped under certain conditions whence the name of sickle-cell anaemia.

These sickled red blood cells tend to pile together, creating clots, and blocking the flow of blood through vessels and thus causing vaso-occlusive crises.

The disease is accompanied by varying degrees of anaemia and chronic complications may appear that affect various organs, e.g. hepatic or renal impairment and retarded growth.

The clinical expression of the disease and its evolution are highly variable among individuals.

Painful vaso-occlusive crises are the most common cause of hospitalisation in sickle cell anaemia patients, and therefore represent a very high cost for society.

Hydroxyurea is currently recognised as the reference drug treatment for this disease.

Approximately 100,000 persons suffer from sickle cell anaemia in the USA compared with approximately 60,000 in Europe. In both cases, it is considered to be a rare disease (less than 5 cases per 10,000 inhabitants)

About ADDMEDICA

Founded in 2005, ADDMEDICA is a pharmaceutical company based in France, focused on developing and marketing medical products for rare diseases and unmet medical needs. ADDMEDICA’s main therapeutic and development fields are

• Genetic diseases and their treatment,

• Organ transplant and tissue replacement,

• Wound healing and tissue regeneration.

ADDMEDICA developed Siklos® specifically for sickle cell anaemia. In 2007, ADDMEDICA obtained a marketing authorisation in Europe for Siklos®, the first and sole medicinal product indicated in the prevention of recurrent painful vaso-occlusive crises in sickle cell anaemia. ADDMEDICA now has FDA-approval for Silos® in the treatment of sickle cell disease in paediatric patients 2 years of age and older. Based on its expertise in the field, ADDMEDICA is pursuing the international development of Siklos®.

For more information: http://www.addmedica.com

About Medunik USA

Based in Pennsylvania, Medunik USA works to improve the health and quality of life of Americans living with rare diseases by making several orphan drug therapies available in the United States. With strategic partnerships worldwide, the company has critical experience in approval and market access processes as well as the marketing of orphan drug therapies. For more information: www.medunikusa.com.

Sources:

Concerning the disease

https://www.nhlbi.nih.gov/health/health-topics/topics/sca

https://www.orpha.net/data/patho/Pub/fr/Drepanocytose-FRfrPub125v01.pdf

Concerning Siklos® in the USA

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf

Concerning Siklos® in Europe

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000689/human_med_001050.jsp&mid=WC0b01ac058001d125&murl=menus/medicines/medicines.jsp

Concerning Escort-HU

https://clinicaltrials.gov/ct2/show/NCT02516579

Contact information

Yucatan
Caroline Prince
cprince@yucatan.fr

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Earth Networks Launches Aviation Early Warning System for the Agency for the Safety of Air Navigation in Africa and Madagascar (ASECNA)25.3.2019 02:00:00 EETTiedote

Earth Networks today announced it has completed a new aviation early weather warning system for The Agency for the Safety of Air Navigation in Africa and Madagascar (ASECNA). The announcement was made at the 6th annual InterMET Asia conference in Singapore. Designed for air traffic management and airport operations professionals to issue alerts on severe weather and lightning threats that have the potential to affect air and land operations including ground crews, fueling, and aircraft, the newly operational global aviation early warning system includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network, featuring over 1,700 sensors in more than 100 countries On-the-ground weather monitoring via the Earth Networks Weather Network Sferic Maps, a web-based severe weather monitoring and alerting platform Severe weather data and visualization tools such as Dangerous Thunderstorm Alerts and PulseRad, a lightning-derived radar alternative Short-range point f

PIVOT Fintech Gets Capital Markets Services License From The Monetary Authority Of Singapore25.3.2019 00:30:00 EETTiedote

PIVOT Fintech Pte. Ltd. (“PIVOT”), the digital wealth management technology services venture backed by Pintec Technology Holdings Ltd. (“PINTEC”; NASDAQ: PT) and FWD Group announced today that it has been granted a Capital Markets Services (“CMS”) license by the Monetary Authority of Singapore (MAS). PIVOT’s CMS license, which comes after the recently published MAS Guidelines on the Provision of Digital Advisory Services on 8 October 2018, allows the company to offer AI-driven investment services directly to retail clients. “This significant Singapore milestone marks the start of PIVOT’s ambition to deliver innovative wealth management solutions in Southeast Asia,” said PIVOT CEO Victor Lye, who created PIVOT’s proprietary gamified risk profiling analytics to drive financial inclusiveness. PIVOT’s core shareholder, PINTEC, has proven technology and expertise in delivering AI-driven global asset allocation and money management services to financial institutions in the highly competitive

1.1 Million People Benefit from the UAE-based Big Heart Foundation’s Humanitarian Efforts in 201824.3.2019 22:21:00 EETTiedote

Humanitarian aid worth US$ 15.8 million (AED 58 million) to 1,091,000 million refugees, internally displaced and acutely disadvantaged people in 12 conflict-laden nations worldwide has been offered by The Big Heart Foundation (TBHF), a leading international humanitarian organisation based in Sharjah, UAE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190324005019/en/ (TBHF Graphic) Operating under the leadership of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, UNHCR Eminent Advocate and TBHF Chairperson, the humanitarian non-profit operating out of Sharjah – the third largest emirate in United Arab Emirates (UAE) – has mobilised the funds to support and initiate 20 projects in collaboration with UNHCR, Doctors without Borders (Médecins Sans Frontières) in vital sectors of food security, healthcare and education. Their 2018 efforts spanned 12 countries, namely, Bangladesh, Egypt, Iraq, Jordan, Malaysia, Pakistan, Pal

SCG Chemicals Company chooses gPROMS modelling for digital design and operations22.3.2019 18:55:00 EETTiedote

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations. SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants. Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables u

Logicor Announces Results for Year Ended 31 December 201822.3.2019 17:29:00 EETTiedote

Logicor announces strong financial performance for the year ended 31 December Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%). Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe. EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps). LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x. Capital Structure In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of

Delticom AG/Mytyres.co.uk: Buying Great Value Tyres Online Doesn’t Mean Missing out on Professional Fitting22.3.2019 17:15:00 EETTiedote

Spring is just around the corner, and it’s time for drivers to start thinking about changing to summer tyres. However, a tyre check may show that your current summer tyres are getting old, worn out, or have visible damage, such as cracks or bumps. If this is the case, then it's time for a new set of tyres. The legal minimum tread depth is 1.6 mm, however experts recommend significantly more – summer tyres should be replaced even if the tread depth is 3 mm. Regardless of mileage, you should change your tyres at least every eight to ten years. This is because the rubber starts to harden, the tyres lose grip on the road, and driving performance is affected. Of course, a set of four new tyres is a significant investment – authorised workshops can often charge between 250 and 350 pounds. If you want to save money, consider the alternatives: the result is an increasing number of customers turning to online shops such as Mytyres.co.uk to buy new tyres. The market share of tyres sold online ha

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme